All In Biotech

NDA 215428 · Almatica

Citalopram Hydrobromide

Citalopram Hydrobromide · Oral

Last checked: Nov 19, 2026Latest source record: Aug 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Jan 31, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

220

32 Phase 3, 6 recruiting

FAERS reports

107,749

88,370 serious, 17,192 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )]. Citalopram Capsules is not approved for use in pediatric patients [see Use in Specific Populations ( 8.4 )]. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). Citalopram Capsules is not approved for use in pediatric patients ( 8.4 ).

What it is approved for

From the label in effect Oct 7, 2025.

Citalopram Capsules are indicated for the treatment of Major Depressive Disorder (MDD) in adults [see Clinical Studies ( 14 )] . Citalopram Capsules is a selective serotonin reuptake inhibitor (SSRI) indicated for treatment of Major Depressive Disorder (MDD) in adults. ( 1 )

Mechanism: The mechanism of action of citalopram as an antidepressant is unclear, but is presumed to be related to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 31, 2022 Original approval · Type 2 - New Active Ingredient and Type 3 - New Dosage Form LetterLabelReview
1 products under this application
  • CITALOPRAM HYDROBROMIDE · CITALOPRAM HYDROBROMIDE EQ 30MG BASE · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Citalopram Hydrobromide" as an intervention, any sponsor and status, largest first.

All 220 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue7,087
  • nausea6,075
  • drug ineffective5,636
  • headache5,236
  • toxicity to various agents5,192
  • diarrhoea4,873
  • fall4,497
  • pain4,483
  • dizziness4,467
  • off label use4,427
  • completed suicide4,228
  • dyspnoea4,187

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004803
20051,012
20061,091
20071,414
20082,043
20092,348
20102,849
20113,921
20124,855
20134,751
20145,906
20157,383
20167,684
20177,125
20188,132
20198,606
20207,289
20216,249
20225,329
20235,387
20245,021
20255,202
20263,346

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 8 on PubMed

Sponsor: Almatica

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.